|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
|
AU6887996A
(en)
|
1995-09-01 |
1997-04-01 |
Washington University School Of Medicine |
Method of reducing neurotoxic injury with zinc chelators
|
|
PL329070A1
(en)
|
1996-03-22 |
1999-03-15 |
Du Pont Pharm Co |
Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
|
|
AU740603B2
(en)
|
1997-06-02 |
2001-11-08 |
Janssen Pharmaceutica N.V. |
(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
|
|
CA2296314A1
(en)
|
1997-07-25 |
1999-02-04 |
Merck & Co., Inc. |
Cyclic amine modulators of chemokine receptor activity
|
|
KR20010015639A
(ko)
|
1997-09-30 |
2001-02-26 |
스즈키 다다시 |
술포닐 유도체
|
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
|
EP1039899A2
(en)
|
1997-12-19 |
2000-10-04 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
|
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
|
AP1654A
(en)
|
1999-03-24 |
2006-09-01 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds.
|
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
|
JP2003513970A
(ja)
*
|
1999-11-08 |
2003-04-15 |
ワイス |
中枢神経系障害の治療のための［（インドール−３−イル）−シクロアルキル］−３−置換アゼチジン
|
|
US6602872B1
(en)
|
1999-12-13 |
2003-08-05 |
Merck & Co., Inc. |
Substituted pyridazines having cytokine inhibitory activity
|
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
HK1052011A1
(zh)
|
2000-09-15 |
2003-08-29 |
Anormed Inc. |
趋化因子受体结合杂环化合物
|
|
DE60137435D1
(de)
|
2000-09-15 |
2009-03-05 |
Anormed Inc |
Chemokin rezeptor bindenden heterozyklische verbindungen
|
|
US6734191B2
(en)
|
2000-09-15 |
2004-05-11 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds
|
|
NZ526622A
(en)
|
2000-12-11 |
2006-07-28 |
Amgen Sf Llc |
CXCR3 antagonists
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
|
DK1411918T3
(da)
|
2001-07-31 |
2012-04-23 |
Genzyme Global S A R L |
Fremgangsmåder til at mobilisere progenitor/stamceller
|
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
|
JP4431389B2
(ja)
|
2001-09-12 |
2010-03-10 |
アノーメッド インコーポレイティド |
鏡像異性的に純粋なアミノ置換縮合二環式環の合成
|
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
PL369856A1
(en)
|
2001-12-21 |
2005-05-02 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
|
US7074809B2
(en)
|
2002-08-09 |
2006-07-11 |
Astrazeneca Ab |
Compounds
|
|
PT1536827E
(pt)
|
2002-08-14 |
2009-03-20 |
Silence Therapeutics Ag |
Utilização de proteína cinase n beta
|
|
EP1571146A4
(en)
|
2002-12-10 |
2010-09-01 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
|
|
AU2004228668B2
(en)
|
2003-04-03 |
2011-10-27 |
Park Funding, Llc |
PI-3 kinase inhibitor prodrugs
|
|
WO2004091518A2
(en)
|
2003-04-11 |
2004-10-28 |
Anormed Inc. |
Cxcr4 chemokine receptor binding compounds
|
|
JP4778420B2
(ja)
|
2003-04-22 |
2011-09-21 |
アノーメッド インコーポレイティド |
増強された有効性を有するケモカインレセプタ結合複素環式化合物
|
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
|
EP1692153A4
(en)
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
|
EP1730113B1
(en)
|
2004-03-15 |
2016-12-28 |
Genzyme Corporation |
Process for the synthesis of a cxcr4 antagonist
|
|
CA2561718A1
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
MX2007001514A
(es)
|
2004-08-02 |
2007-03-27 |
Smithkline Beecham Corp |
Compuestos quimicos.
|
|
WO2006023400A2
(en)
|
2004-08-16 |
2006-03-02 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
MX2007002679A
(es)
|
2004-09-02 |
2007-05-16 |
Smithkline Beecham Corp |
Compuestos quimicos.
|
|
WO2006036816A2
(en)
|
2004-09-24 |
2006-04-06 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
WO2006096444A2
(en)
|
2005-03-04 |
2006-09-14 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
ATE476529T1
(de)
|
2005-07-08 |
2010-08-15 |
Siemens Healthcare Diagnostics |
Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
|
|
EP1904501A2
(en)
|
2005-07-11 |
2008-04-02 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
CA2617436A1
(en)
|
2005-08-02 |
2007-02-08 |
Ineos Europe Limited |
Diene polymerisation catalysts comprising two or more transition metals
|
|
US20070043012A1
(en)
|
2005-08-19 |
2007-02-22 |
Bridger Gary J |
Methods to enhance chemotherapy
|
|
JP2009507795A
(ja)
|
2005-08-31 |
2009-02-26 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
US7989622B2
(en)
|
2005-10-07 |
2011-08-02 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
WO2007058322A1
(ja)
|
2005-11-18 |
2007-05-24 |
Ono Pharmaceutical Co., Ltd. |
塩基性基を含有する化合物およびその用途
|
|
JP2009517474A
(ja)
|
2005-11-30 |
2009-04-30 |
シェーリング コーポレイション |
Ｃｃｒ５拮抗剤およびｃｘｃｒ４拮抗剤の組み合わせを含む組成物
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
PE20070946A1
(es)
|
2006-01-25 |
2007-10-16 |
Smithkline Beecham Corp |
COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
|
|
JP2009524689A
(ja)
|
2006-01-25 |
2009-07-02 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
|
WO2007129161A2
(en)
|
2006-04-26 |
2007-11-15 |
F. Hoffmann-La Roche Ag |
Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
|
|
MX2008014296A
(es)
|
2006-06-12 |
2009-03-06 |
Pfizer Prod Inc |
Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih.
|
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
CN101631786A
(zh)
|
2006-12-20 |
2010-01-20 |
先灵公司 |
新颖的jnk抑制剂
|
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
EP1974729A1
(en)
|
2007-03-28 |
2008-10-01 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
|
|
ES2395583T3
(es)
|
2007-05-10 |
2013-02-13 |
Ge Healthcare Limited |
IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
CA2695989A1
(en)
|
2007-08-10 |
2009-02-19 |
Glaxosmithkline Llc |
Certain nitrogen containing bicyclic chemical entities for treating viral infections
|
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
|
US9101628B2
(en)
*
|
2007-09-18 |
2015-08-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and composition of treating a flaviviridae family viral infection
|
|
US20110052562A1
(en)
*
|
2007-12-19 |
2011-03-03 |
The Scripps Research Institute |
Benzimidazoles and analogs as rho kinase inhibitors
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
NZ588033A
(en)
|
2008-03-20 |
2012-11-30 |
Carolus Therapeutics Inc |
Methods of treating a mif-mediated disorder
|
|
BRPI0909375A2
(pt)
|
2008-03-28 |
2015-08-04 |
Altiris Therapeutics |
Moduladores de receptores de quimiocinas
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP2010016628A
(ja)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
WO2011036270A1
(en)
|
2009-09-28 |
2011-03-31 |
Kerry Group Services International Limited |
Pharmaceutical composition
|
|
WO2011050245A1
(en)
|
2009-10-23 |
2011-04-28 |
Yangbo Feng |
Bicyclic heteroaryls as kinase inhibitors
|
|
US20110293686A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
|
WO2012047339A2
(en)
|
2010-06-28 |
2012-04-12 |
The General Hospital Corporation |
Anti-cxcr4 as a sensitizer to cancer therapeutics
|
|
US9079880B2
(en)
|
2010-07-07 |
2015-07-14 |
Boehringer Ingelheim International Gmbh |
Rho kinase inhibitors
|
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
|
US9267934B2
(en)
|
2010-10-26 |
2016-02-23 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
|
CA2815179A1
(en)
|
2010-11-10 |
2012-05-18 |
Actelion Pharmaceuticals Ltd |
Lactam derivatives useful as orexin receptor antagonists
|
|
AU2011336397B2
(en)
|
2010-12-03 |
2016-12-15 |
Emory University |
Chemokine CXCR4 receptor modulators and uses related thereto
|
|
US8435993B2
(en)
|
2010-12-07 |
2013-05-07 |
Philadelphia Health And Education Corporation |
Methods of inhibiting metastasis from cancer
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN107899012A
(zh)
|
2011-01-11 |
2018-04-13 |
戴麦里克斯生物科学有限公司 |
联合疗法
|
|
KR20140045411A
(ko)
*
|
2011-05-16 |
2014-04-16 |
젠자임 코포레이션 |
Ｃｘｃｒ４ 길항제의 용도
|
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
|
CA2849820C
(en)
|
2011-09-26 |
2019-08-27 |
Merck Patent Gmbh |
Benzyl piperidine compounds as lysophosphatidic acid (lpa) receptor antagonist
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA2860995A1
(en)
|
2012-01-12 |
2013-07-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
|
WO2014082083A1
(en)
|
2012-11-26 |
2014-05-30 |
Caris Science, Inc. |
Biomarker compositions and methods
|
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
|
EP3473299A1
(en)
|
2013-06-05 |
2019-04-24 |
Salk Institute for Biological Studies |
Vitamin d receptor agonists to treat diseases involving cxcl12 activity
|
|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
CA2920377A1
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
|
PT3038601T
(pt)
|
2013-08-27 |
2020-06-30 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
|
AU2014318614B2
(en)
|
2013-09-12 |
2021-01-07 |
Dana-Farber Cancer Institute Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
WO2015143092A1
(en)
|
2014-03-18 |
2015-09-24 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
|
MX382033B
(es)
|
2014-03-19 |
2025-03-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
|
|
WO2015200341A1
(en)
|
2014-06-23 |
2015-12-30 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
|
RU2696312C2
(ru)
|
2014-07-16 |
2019-08-01 |
Трансген Са |
Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
|
|
CA2970114A1
(en)
|
2014-12-12 |
2016-06-16 |
Commonwealth Scientific And Industrial Research Organisation |
Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
JP2018516969A
(ja)
|
2015-06-12 |
2018-06-28 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
|
|
WO2017048702A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
|
CN109069426B
(zh)
|
2015-12-14 |
2021-10-29 |
X4 制药有限公司 |
治疗癌症的方法
|
|
CA3008279A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
WO2017112894A1
(en)
|
2015-12-22 |
2017-06-29 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
|
CN108883132A
(zh)
|
2016-01-22 |
2018-11-23 |
X4 制药有限公司 |
用于治疗癌症的方法
|
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
JP7128399B2
(ja)
|
2016-04-14 |
2022-08-31 |
クリエイティブ マイクロテック インコーポレーテッド |
癌治療のための治療決定におけるｐｄ－ｌ１発現の使用方法
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
|
JP2020525427A
(ja)
|
2017-06-21 |
2020-08-27 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
癌を処置するための方法
|
|
JP2021502071A
(ja)
|
2017-11-07 |
2021-01-28 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
がんバイオマーカーおよびその使用方法
|
|
WO2019126106A1
(en)
|
2017-12-19 |
2019-06-27 |
X4 Pharmaceuticals, Inc. |
Acyclic cxcr4 inhibitors and uses thereof
|
|
WO2019200223A1
(en)
|
2018-04-13 |
2019-10-17 |
X4 Pharmaceuticals, Inc. |
Cancer serum biomarkers and methods of use thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|